Pular para conteúdo

Oncologia 

Manejo da anemia

Agentes estimuladores da eritropoese

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (abre nova janela)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Fonte‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indexado‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (abre nova janela)

Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma. (abre nova janela)

Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.

Fonte‎: Acta Haematol 2007;117(3):162-7.

Indexado‎: PubMed 17148935

DOI‎: 10.1159/000097464

https://www.ncbi.nlm.nih.gov/pubmed/17148935 (abre nova janela)

Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial. (abre nova janela)

Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.

Fonte‎: Am J Hematol 2013;88(12):990-6.

Indexado‎: PubMed 23873823

DOI‎: 10.1002/ajh.23552

https://www.ncbi.nlm.nih.gov/pubmed/23873823 (abre nova janela)

Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. (abre nova janela)

Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.

Fonte‎: J Clin Oncol 2011;29(28):3791-7.

Indexado‎: PubMed 21860000

DOI‎: 10.1200/JCO.2010.30.4899

https://www.ncbi.nlm.nih.gov/pubmed/21860000 (abre nova janela)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (abre nova janela)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Fonte‎: Cancer 2012;118(3):848-55.

Indexado‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (abre nova janela)

Management of anemia in cancer patients. (abre nova janela)

Calabrich A, Katz A.

Fonte‎: Future Oncol 2011;7(4):507-17.

Indexado‎: PubMed 21463140

DOI‎: 10.2217/fon.11.24

https://www.ncbi.nlm.nih.gov/pubmed/21463140 (abre nova janela)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (abre nova janela)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Fonte‎: BJU Int 2011;108(10):1582-7.

Indexado‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (abre nova janela)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (abre nova janela)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Fonte‎: J Clin Oncol 2010;28(13):2239-45.

Indexado‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (abre nova janela)

Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. (abre nova janela)

Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.

Fonte‎: Br J Cancer 2011;105(9):1267-72.

Indexado‎: PubMed 21959870

DOI‎: 10.1038/bjc.2011.395

https://www.ncbi.nlm.nih.gov/pubmed/21959870 (abre nova janela)

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. (abre nova janela)

Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.

Fonte‎: J Intern Med 2017;281(3):284-99.

Indexado‎: PubMed 27926979

DOI‎: 10.1111/joim.12579

https://www.ncbi.nlm.nih.gov/pubmed/27926979 (abre nova janela)

How I treat cancer-associated anemia. (abre nova janela)

Gilreath JA, Rodgers GM

Fonte‎: Blood 2020;136(7):801-13.

Indexado‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (abre nova janela)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (abre nova janela)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Fonte‎: Eur J Haematol. 2023 110(4):354-61.

Indexado‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (abre nova janela)

A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes. (abre nova janela)

Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.

Fonte‎: Int J Hematol 2015;102(4):401-12.

Indexado‎: PubMed 26323997

DOI‎: 10.1007/s12185-015-1862-5

https://www.ncbi.nlm.nih.gov/pubmed/26323997 (abre nova janela)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (abre nova janela)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Fonte‎: Cancer 2013;119(1):107-14.

Indexado‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (abre nova janela)

Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial. (abre nova janela)

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.

Fonte‎: J Natl Cancer Inst 2013;105(14):1018-26.

Indexado‎: PubMed 23860204

DOI‎: 10.1093/jnci/djt145

https://www.ncbi.nlm.nih.gov/pubmed/23860204 (abre nova janela)

Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. (abre nova janela)

Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.

Fonte‎: Cancer Sci 2013;104(4):481-5.

Indexado‎: PubMed 23331490

DOI‎: 10.1111/cas.12105

https://www.ncbi.nlm.nih.gov/pubmed/23331490 (abre nova janela)

Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. (abre nova janela)

Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, Fenaux P

Fonte‎: Br J Haematol 2019;184(2):134-60.

Indexado‎: PubMed 30549002

DOI‎: 10.1111/bjh.15707

https://www.ncbi.nlm.nih.gov/pubmed/30549002 (abre nova janela)

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. (abre nova janela)

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

Fonte‎: Support Care Cancer 2012;20(1):159-65.

Indexado‎: PubMed 21359879

DOI‎: 10.1007/s00520-010-1083-7

https://www.ncbi.nlm.nih.gov/pubmed/21359879 (abre nova janela)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (abre nova janela)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Fonte‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indexado‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (abre nova janela)

Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial. (abre nova janela)

Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.

Fonte‎: Oncologist 2010;15(9):935-43.

Indexado‎: PubMed 20798194

DOI‎: 10.1634/theoncologist.2009-0279

https://www.ncbi.nlm.nih.gov/pubmed/20798194 (abre nova janela)

Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. (abre nova janela)

Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.

Fonte‎: Lung Cancer 2012;76(3):478-85.

Indexado‎: PubMed 22277104

DOI‎: 10.1016/j.lungcan.2011.12.015

https://www.ncbi.nlm.nih.gov/pubmed/22277104 (abre nova janela)

Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. (abre nova janela)

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.

Fonte‎: Eur J Haematol 2016;97(1):33-8.

Indexado‎: PubMed 26341961

DOI‎: 10.1111/ejh.12679

https://www.ncbi.nlm.nih.gov/pubmed/26341961 (abre nova janela)

Ferro intravenoso 

Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. (abre nova janela)

Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascón P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H, Österborg A, Pronzato P, Santini V, Schrijvers D, Stauder R, Jordan K, Herrstedt J; ESMO Guidelines Committee

Fonte‎: Ann Oncol 2018;29(Supplement_4):iv96-110.

Indexado‎: PubMed 29471514

DOI‎: 10.1093/annonc/mdx758

https://www.ncbi.nlm.nih.gov/pubmed/29471514 (abre nova janela)

Intravenous iron in oncology. (abre nova janela)

Auerbach M, Ballard H.

Fonte‎: J Natl Compr Canc Netw 2008;6(6):585-92.

Indexado‎: PubMed 18597712

https://www.ncbi.nlm.nih.gov/pubmed/18597712 (abre nova janela)

Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. (abre nova janela)

Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.

Fonte‎: Int J Colorectal Dis 2016;31(3):543-51.

Indexado‎: PubMed 26694926

DOI‎: 10.1007/s00384-015-2461-x

https://www.ncbi.nlm.nih.gov/pubmed/26694926 (abre nova janela)

How I treat cancer-associated anemia. (abre nova janela)

Gilreath JA, Rodgers GM

Fonte‎: Blood 2020;136(7):801-13.

Indexado‎: PubMed 32556170

DOI‎: 10.1182/blood.2019004017

https://www.ncbi.nlm.nih.gov/pubmed/32556170 (abre nova janela)

Total dose iron dextran infusion in cancer patients: is it SaFe2+? (abre nova janela)

Gilreath JA, Stenehjem DD, Rodgers GM.

Fonte‎: J Natl Compr Canc Netw 2012;10(5):669-76.

Indexado‎: PubMed 22570295

https://www.ncbi.nlm.nih.gov/pubmed/22570295 (abre nova janela)

Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia. (abre nova janela)

Inzoli E, Crisà E, Pugliese N, Civettini I, Lanzarone G, Castelli A, Martinelli V, Montelisciani L, Antolini L, Gambacorti-Passerini C, Elli EM

Fonte‎: Eur J Haematol. 2023 110(4):354-61.

Indexado‎: PubMed 36480004

DOI‎: 10.1111/ejh.13910

https://pubmed.ncbi.nlm.nih.gov/36480004/ (abre nova janela)

Intravenous iron therapy to treat anemia in oncology: a mapping review of randomized controlled trials. (abre nova janela)

Lim J, Auerbach M, MacLean B, Al-Sharea A, Richards T

Fonte‎: Curr Oncol. 2023 24;30(9):7836-51.

Indexado‎: PubMed 37754484

DOI‎: 10.3390/curroncol30090569

https://pubmed.ncbi.nlm.nih.gov/37754484/ (abre nova janela)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (abre nova janela)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Fonte‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indexado‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (abre nova janela)

Perioperative anemia management in colorectal cancer patients: a pragmatic approach. (abre nova janela)

Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.

Fonte‎: World J Gastroenterol 2014;20(8):1972-85.

Indexado‎: PubMed 24587673

DOI‎: 10.3748/wjg.v20.i8.1972

https://www.ncbi.nlm.nih.gov/pubmed/24587673 (abre nova janela)

Practical clinical consensus guidelines for the management of cancer associated anemia in low- and middle-income countries. (abre nova janela)

Parikh PM, Aggarwal S, Biswas G, Gulia S, Agarwala V, Basade M, Mohapatra PN, Vamshi KM, Warrier A, Prasad K, Roy P, Chandrakant MV, Malhotra H, Hingmire S, Paul D, Maniar V, Gupta A, Panda SS, Samar A, Rohatgi N, Dattatreya S, Krishnamurthy M, Thirumalairaj R

Fonte‎: South Asian J Cancer. 2023 15;12(2):93-9.

Indexado‎: PubMed 37969669

DOI‎: 10.1055/s-0043-1771445

https://pubmed.ncbi.nlm.nih.gov/37969669/ (abre nova janela)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (abre nova janela)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Fonte‎: J Clin Oncol 2008;26(10):1619-25.

Indexado‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (abre nova janela)

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. (abre nova janela)

Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.

Fonte‎: J Cancer Res Clin Oncol 2012;138(2):179-87.

Indexado‎: PubMed 21972052

DOI‎: 10.1007/s00432-011-1072-3

https://www.ncbi.nlm.nih.gov/pubmed/21972052 (abre nova janela)

Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. (abre nova janela)

Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.

Fonte‎: Ann Oncol 2013;24(2):475-82.

Indexado‎: PubMed 23071262

DOI‎: 10.1093/annonc/mds338

https://www.ncbi.nlm.nih.gov/pubmed/23071262 (abre nova janela)

ONCOLOGIA 
Manejo da anemia
Português (Brasil)
Manejo da anemia
https://assetsnffrgf-a.akamaihd.net/assets/ct/5a91b826b0/images/syn_placeholder_sqr.png

Contate um representante da Comissão de Ligação com Hospitais

Um serviço mundial gratuito disponível 24 horas por dia para médicos que tratam Testemunhas de Jeová.

Contato

Conteúdos para baixar

Assuntos incluem: métodos clínicos para controlar hemorragia e anemia sem o uso de transfusões de sangue, a posição ética e religiosa das Testemunhas de Jeová sobre tratamentos médicos e uma descrição da contribuição que as Testemunhas de Jeová fazem na área médica por meio das Comissões de Ligação com Hospitais.

Visualizar downloads

Vídeos

Opções de tratamento e considerações médicas e éticas para médicos que tratam Testemunhas de Jeová.

Vídeos